Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Jul 9. doi: 10.1038/s41375-018-0177-y. [Epub ahead of print]

PMID:
29985446
2.

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.

Ernst T, Busch M, Rinke J, Ernst J, Haferlach C, Beck JF, Hochhaus A, Gruhn B.

Leukemia. 2018 Jun 13. doi: 10.1038/s41375-018-0157-2. [Epub ahead of print] No abstract available.

PMID:
29899367
3.

Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases.

Baer C, Pohlkamp C, Haferlach C, Kern W, Haferlach T.

Leukemia. 2018 Mar 30. doi: 10.1038/s41375-018-0119-8. [Epub ahead of print] No abstract available.

PMID:
29725031
4.

The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T.

Haematologica. 2018 May;103(5):e192-e195. doi: 10.3324/haematol.2017.183160. No abstract available.

5.

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2018 Mar 6. doi: 10.1038/s41375-018-0086-0. [Epub ahead of print] No abstract available.

PMID:
29568097
6.

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.

Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, Haferlach T.

Leukemia. 2018 May;32(5):1249-1253. doi: 10.1038/s41375-018-0026-z. Epub 2018 Jan 30. No abstract available.

PMID:
29568090
7.

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2.

Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T.

Haematologica. 2018 Mar 22. pii: haematol.2017.187302. doi: 10.3324/haematol.2017.187302. [Epub ahead of print] No abstract available.

8.

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.

PMID:
29479069
9.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0033-0. [Epub ahead of print] Erratum in: Leukemia. 2018 Jul 9;:.

PMID:
29467491
10.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.

PMID:
29341334
11.

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.

ĹAbbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2017 Nov 28. doi: 10.1038/leu.2017.337. [Epub ahead of print]

PMID:
29180669
12.

Smoldering Development of Acute Megakaryoblastic Leukemia with Clonal Evolution in an Infant without Down Syndrome.

Schmidt E, Fischer U, Biskup W, Haferlach C, Meisel R, Kuhlen M, Borkhardt A.

Klin Padiatr. 2017 Nov;229(6):352-354. doi: 10.1055/s-0043-113446. Epub 2017 Nov 13. No abstract available.

PMID:
29132167
13.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
14.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

15.

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C.

Leukemia. 2018 Feb;32(2):295-302. doi: 10.1038/leu.2017.239. Epub 2017 Jul 28.

PMID:
28751771
16.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.

PMID:
28725989
17.
18.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.

Rio-Machin A, Gómez-López G, Muñoz J, Garcia-Martinez F, Maiques-Diaz A, Alvarez S, Salgado RN, Shrestha M, Torres-Ruiz R, Haferlach C, Larráyoz MJ, Calasanz MJ, Fitzgibbon J, Cigudosa JC.

Leukemia. 2017 Sep;31(9):2000-2005. doi: 10.1038/leu.2017.194. Epub 2017 Jun 20. No abstract available.

19.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.

PMID:
28626218
20.

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.

Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann WK, Mossner M.

J Med Genet. 2017 Sep;54(9):640-650. doi: 10.1136/jmedgenet-2017-104528. Epub 2017 Jun 9.

21.

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leukemia. 2017 Sep;31(9):1995-1997. doi: 10.1038/leu.2017.180. Epub 2017 Jun 8. No abstract available.

PMID:
28592886
22.

Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse.

Fasan A, Haferlach C, Perglerovà K, Kern W, Haferlach T.

Haematologica. 2017 Jun;102(6):e222-e224. doi: 10.3324/haematol.2016.162206. Epub 2017 Mar 24. No abstract available.

23.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H, Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H, Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA, Maciejewski JP, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S.

Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.

24.

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia.

Martin-Cabrera P, Jeromin S, Perglerovà K, Haferlach C, Kern W, Haferlach T.

Haematologica. 2017 Apr;102(4):e125-e128. doi: 10.3324/haematol.2016.156844. Epub 2017 Jan 5. No abstract available.

25.

Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

PMID:
27992414
26.
27.

Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients.

Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2016 Nov 14. doi: 10.1002/cyto.b.21493. [Epub ahead of print] No abstract available.

28.

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Baer C, Dicker F, Kern W, Haferlach T, Haferlach C.

Leukemia. 2017 Jun;31(6):1355-1362. doi: 10.1038/leu.2016.330. Epub 2016 Nov 14.

PMID:
27840426
29.

MYC rearranged B-cell neoplasms: Impact of genetics on classification.

Haberl S, Haferlach T, Stengel A, Jeromin S, Kern W, Haferlach C.

Cancer Genet. 2016 Oct;209(10):431-439. doi: 10.1016/j.cancergen.2016.08.007. Epub 2016 Sep 14.

PMID:
27810071
30.

Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.

Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, Yoshizato T, Sato-Otsubo A, Kataoka K, Shiraishi Y, Chiba K, Tanaka H, Ishiyama K, Miyawaki S, Mori H, Nakamaki T, Kihara R, Kiyoi H, Koeffler HP, Shih LY, Miyano S, Naoe T, Haferlach C, Kern W, Haferlach T, Ogawa S, Yoshida K.

Leukemia. 2016 Nov;30(11):2270-2273. doi: 10.1038/leu.2016.212. Epub 2016 Aug 1. No abstract available.

PMID:
27479181
31.

Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations.

Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W.

Leukemia. 2016 Nov;30(11):2251-2253. doi: 10.1038/leu.2016.189. Epub 2016 Jul 14. No abstract available.

PMID:
27411488
32.

Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations.

Vetro C, Haferlach C, Haferlach T, Zenger M, Nadarajah N, Kern W, Meggendorfer M.

Leukemia. 2016 Nov;30(11):2235-2238. doi: 10.1038/leu.2016.158. Epub 2016 May 25. No abstract available.

PMID:
27220668
33.

Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.

Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M.

Br J Haematol. 2016 Nov;175(3):419-426. doi: 10.1111/bjh.14269. Epub 2016 Jul 22.

PMID:
27447873
34.

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C.

Leukemia. 2017 Mar;31(3):705-711. doi: 10.1038/leu.2016.263. Epub 2016 Sep 29.

PMID:
27680515
35.

Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.

Weber S, Haferlach T, Alpermann T, Perglerová K, Schnittger S, Haferlach C, Kern W.

Br J Haematol. 2016 Dec;175(5):904-916. doi: 10.1111/bjh.14343. Epub 2016 Sep 23.

PMID:
27662611
36.

Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.

Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C.

Cancer. 2016 Dec 15;122(24):3821-3830. doi: 10.1002/cncr.30220. Epub 2016 Aug 16.

37.

Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus.

Gyárfás T, Wintgens J, Biskup W, Oschlies I, Klapper W, Siebert R, Bens S, Haferlach C, Meisel R, Kuhlen M, Borkhardt A.

Mol Cell Pediatr. 2016 Dec;3(1):30. doi: 10.1186/s40348-016-0061-7. Epub 2016 Aug 29.

38.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M.

Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030. Epub 2016 Jul 6.

39.

Subtype-specific patterns of molecular mutations in acute myeloid leukemia.

Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C.

Leukemia. 2017 Jan;31(1):11-17. doi: 10.1038/leu.2016.163. Epub 2016 Jun 10.

PMID:
27285584
40.

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D.

Blood. 2016 Sep 1;128(9):1246-59. doi: 10.1182/blood-2015-11-679167. Epub 2016 Jun 6.

41.

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.

Groepper S, Schlue J, Haferlach C, Giagounidis A.

Oncol Res Treat. 2016;39(6):384-7. doi: 10.1159/000446029. Epub 2016 May 25.

42.

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.

Haferlach T, Weber S, Konietschke R, Nadarajah N, Stengel A, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2123-2125. doi: 10.1038/leu.2016.156. Epub 2016 May 25. No abstract available.

PMID:
27220669
43.

The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C.

Genes Chromosomes Cancer. 2016 Oct;55(10):777-85. doi: 10.1002/gcc.22377. Epub 2016 Jul 4.

PMID:
27218649
44.

The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.

Haferlach T, Stengel A, Eckstein S, Perglerová K, Alpermann T, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2109-2112. doi: 10.1038/leu.2016.150. Epub 2016 May 23. No abstract available.

45.

The role of the RAS pathway in iAMP21-ALL.

Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ.

Leukemia. 2016 Sep;30(9):1824-31. doi: 10.1038/leu.2016.80. Epub 2016 Apr 22.

46.

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.

Haematologica. 2016 Jul;101(7):830-8. doi: 10.3324/haematol.2016.145888. Epub 2016 Apr 21.

47.

Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi-allergic donor.

Garzorz N, Thomas J, Eberlein B, Haferlach C, Ring J, Biedermann T, Schmidt-Weber C, Eyerich K, Seifert F, Eyerich S.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1136-9. doi: 10.1111/jdv.13617. Epub 2016 Mar 16.

PMID:
26990607
48.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
49.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
50.

The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.

Meggendorfer M, Haferlach C, Zenger M, Macijewski K, Kern W, Haferlach T.

Leukemia. 2016 Jul;30(7):1624-7. doi: 10.1038/leu.2016.21. Epub 2016 Feb 9. No abstract available.

PMID:
26859077

Supplemental Content

Loading ...
Support Center